Oxford BioMedica PLC (OXBDF)

[marcusl2]

Cancer stem cells (also called cancer-initiating cells) are implicated in tumor initiation, maintenance, and recurrence, leading to the poor effect of standard chemotherapies and tumor recurrence [31]. 5T4 was reported as a potential marker of CSCs in NSCLC squamous cell carcinoma [15]. 5T4-targeting ADC MEDI0641 could effectively kill cancer stem cells and non-cancer stem cells, resulting in regression of tumors such as breast cancer, head and neck squamous cell carcinoma, etc

hTTps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5934552/

CarT 5T4 OXB 302 may prove to be a valuable asset.